Central Insight and Ajos Bio Selected for IT Category at the 2021 VIP ASIA AWARDS

[Asia Economy Reporter Hyunseok Yoo] Central Insight announced on the 5th that AzothBio was awarded as an ‘IT’ sector company at the ‘VIP ASIA AWARDS 2020-21,’ which selects and honors companies that shone in Asia in 2020 and will shine in Asia in 2021.

AzothBio is a specialized new drug development company based on an artificial intelligence platform that has secured technological competitiveness with over 10 models including deep-learning-based drug activity prediction and virtual screening/generation.

Currently, based on artificial intelligence (AI), AzothBio has established an integrated platform (AiDL®) where big data integrated analysis solution (BioDL®) and AI models for new drug development can operate efficiently. The company is conducting clinical trials on five immune oncology drug pipelines and targeted anticancer drugs. The AI platform is being expanded to research on oncology, immune system diseases, as well as neurological system and drug delivery systems. Joint projects for ‘new drug discovery and development’ are being carried out with domestic and international partners including Ewha Medical Center.

In particular, the AI models developed and built with AzothBio’s proprietary technology are data platforms capable of processing, analyzing, and utilizing heterogeneous and diverse forms of data. The platform can shorten the drug candidate discovery period, which traditionally took at least 4 to 6 years, to within 2 years and significantly reduce costs, drawing attention as a future-oriented new drug development platform.

Additionally, AzothBio has recently filed domestic and international patents for peptide substances that induce immune activation effective in treating the Torona19 virus, using its self-developed AI models. The immune activation inducing substances discovered this time are peptide-based synthetic compounds utilizing nucleotide sequence information of the coronavirus. The prediction accuracy test has already been completed through a UK experimental institution, and commercialization discussions are underway both domestically and internationally.

A company official stated, “The AI new drug development platform, which can drastically reduce the time and cost of new drug development by utilizing AI, is emerging as next-generation technology in the global new drug development market,” adding, “Being selected as a company that will shine in Asia in 2021 is a result of external and internal recognition of AzothBio’s technological capabilities. We plan to focus on strengthening market competitiveness as well as AI platform technological competitiveness such as new substance design systems and ultra-fast screening systems.”

‘VIP ASIA AWARDS 2020-21’ is a global award held annually by the global news network AVING. It started in 2005 to select ‘People, place, promotion’ that will shine in Asia and to inform the world of Asian values that will lead global history, culture, and economic trends. This year marks its 15th anniversary.

This content was produced with the assistance of AI translation services.